Common questions about Sklice (FAQ)
Q: Is Sklice the same medicine now that it is available without a prescription?
Sklice (ivermectin) 0.5% lotion was approved by the U.S. Food and Drug Administration (FDA) for non-prescription (OTC) use in October 2020. The medicine remains indicated for the topical treatment of head lice infestations in patients who are 6 months of age and older. This change in status means the product is now available over the counter, while its core function and safety profile are consistent with its regulatory approval.
Q: Does Sklice kill lice eggs (nits) or just the adult lice?
Studies and official product information indicate that Sklice is formulated to kill both lice and their eggs (nits) on the scalp and hair. The active ingredient works through a specific paralyzing mechanism of action that targets the parasite’s biology. This targeted effect is described as eliminating organisms at both the adult and egg stages.
Q: Why do official documents state Sklice is for topical use only?
Regulatory documents strictly specify that Sklice is for use on the scalp and scalp hair only and is not for oral, ophthalmic (eye), or intravaginal use. Regulatory classification establishes this as a strict constraint, as getting the lotion in the eyes can cause irritation. Official labeling requires the product be administered to children only under the direct supervision of an adult to mitigate the risk of accidental ingestion.
Q: Is Sklice considered appropriate for use during pregnancy?
According to the official product information, no human studies have been conducted to determine the safety and effectiveness of Sklice in pregnant women. Given the drug’s minimal systemic absorption following topical use, the risk of fetal harm is not expected, but caution is still advised. The determination of use during pregnancy is a matter for consultation with a healthcare professional.
Q: Does the active ingredient in Sklice pass into breast milk after topical application?
It is not known if the active ingredient in Sklice is present in human breast milk following its topical application. However, regulatory information confirms that the systemic exposure from the topical lotion is much lower than that from oral medication. Official guidance notes that accidental transfer of the product to the breast area, where the infant might directly ingest it, should be avoided.
Q: Are there any specific symptoms that indicate a potentially severe reaction to Sklice?
The pivotal clinical trials reported no serious adverse events related to Sklice, and most side effects are localized to the skin and eyes. However, potential severe allergic reactions or hypersensitivity are possible with any medication. Official documents describe that in the event of difficulty breathing, persistent eye or scalp irritation, or a severe rash, cessation of use and consultation with a healthcare professional are indicated.
Q: Is it necessary to use a fine-toothed comb to remove nits after using Sklice?
The official instructions for Sklice state that nit combing is not necessary for the treatment to successfully work. The drug's effectiveness is established by being free of live lice after a single application. Nonetheless, if a user wishes to remove the remaining dead lice and nits, a fine-toothed comb may be used.
Q: Can one tube of Sklice be shared between two different people?
The Sklice tube is intended for single use to treat a person for a lice infestation. While the entire household should be checked, the official instructions imply individual treatment with one tube per person or infestation. The entire amount needed for one treatment is intended to cover the scalp and hair of the affected individual, using up to the full tube.
Q: Does the effectiveness of Sklice differ in areas where lice have developed resistance to pyrethroid treatments?
Official information indicates that Sklice operates via a mechanism of action that is distinct from that of traditional insecticidal treatments, such as pyrethroids. Its action targets specific chloride channels in the parasites’ nervous system. This distinction in the site of action means the drug is considered to have activity that may differ from older classes of treatment in areas where resistance has developed.
Q: Why do the product instructions emphasize applying Sklice only to dry hair?
The official product instructions explicitly state that the hair and scalp must be dry before the lotion is applied. This is a required administrative step based on the protocol established in the clinical trials that supported the drug's regulatory effectiveness. The instruction is an essential step required for the product to be used as intended.
Q: Is it true that finding nits on the hair after treatment means Sklice did not work?
Official information indicates this is not necessarily the case. Efficacy for Sklice is defined by the proportion of subjects who are free of live lice after treatment. Finding nits after treatment does not automatically indicate failure, as the presence of dead nits is consistent with successful treatment.
Q: What is the typical time frame when official sources suggest re-treating, if needed?
Sklice is described as a single-use product, and re-treatment is not routinely necessary for the same infestation. If live lice are observed 7 days after the application, the official label advises consultation with a healthcare provider regarding other available treatments. The product should not be used again for the same infestation without professional guidance.
Q: Do I need to wash or dry-clean all bedding, clothing, and towels after using Sklice?
Official labeling advises that Sklice is part of an overall lice management program. As part of this program, the label suggests that users should wash (in hot water) or dry-clean all recently worn clothing, hats, used bedding, and towels that the treated person has been in contact with.
Q: If a person is still feeling an itchy scalp after treatment, does that automatically mean the Sklice failed?
Official information indicates that residual itching does not automatically mean the Sklice treatment has failed. Itching has been observed to continue for a period of time following successful treatment, even after the live parasites have been eliminated. Efficacy is based on the absence of live lice, not the presence of residual symptoms.
Q: How long can adult head lice typically survive away from a human host?
Official regulatory guidance focuses on the fact that lice are primarily spread by head-to-head contact. General information referenced by health authorities indicates that adult lice typically do not survive past one or two days without feeding from a human scalp. This provides context for the environmental cleaning measures suggested in the overall lice management program.
Q: What happens if a child accidentally swallows some of the Sklice lotion?
The product is for topical use only, and the label warns against ingestion. Official instructions indicate that if Sklice is accidentally swallowed, calling a healthcare provider or going to the nearest emergency room right away is the required course of action. This underscores the necessity of strict adult supervision during the application process.
Q: Why do the instructions specify rinsing with only water and waiting 24 hours before shampooing?
The official administration protocol requires rinsing the lotion off completely using water only and waiting a full 24 hours before using regular shampoo. This sequence is a required administrative step based on the protocol established during the clinical trials that demonstrated effectiveness. It is essential to follow this instruction for the product to be used as intended.
